Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.29

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received a consensus rating of "Buy" from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $32.29.

CPRX has been the topic of a number of research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the period. Sound Income Strategies LLC purchased a new stake in Catalyst Pharmaceuticals in the 1st quarter worth about $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $65,000. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 2.7 %

Shares of CPRX traded up $0.61 during mid-day trading on Tuesday, hitting $23.37. The stock had a trading volume of 1,551,587 shares, compared to its average volume of 1,111,360. Catalyst Pharmaceuticals has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The company has a market cap of $2.85 billion, a PE ratio of 19.81, a PEG ratio of 3.31 and a beta of 0.70. The company's fifty day simple moving average is $22.99 and its two-hundred day simple moving average is $22.39.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.